Form 8K Atrium Therapeutics Inc For: 13 August
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Atrium Therapeutics Inc (RNA)
The Atrium Therapeutics share price today is 13.20, view NASDAQ RNA stock exchange data. Track the latest Atrium Therapeutics share price with real-time updates on RNA stock performance including market cap, day range, 52-week range and dividend yield. Access RNA charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.96
13.59
52 wk Range
11.13
16.77
RNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.9613.59
52 wk Range
11.1316.77
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RNA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
25.00
Upside
+89.39%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Atrium gets FDA clearance for PRKAG2 syndrome trial- Investing.com
- Form 8K Atrium Therapeutics Inc For: 13 August
- Investing.com
- Atrium gets FDA clearance for PRKAG2 syndrome trial
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 25.00
(+89.39% Upside)
Earnings
Latest Release
13-08-2026
EPS / Forecast
-1.18 / --
Revenue / Forecast
3M / --
Compare RNA to Peers and Sector
Metrics to compare | RNA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRNAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | −2.6x | −0.4x | |
PEG Ratio | - | 0.12 | 0.00 | |
Price/Book | 1.1x | 6.4x | 2.6x | |
Price / LTM Sales | 6.3x | 14.6x | 3.1x | |
Upside (Analyst Target) | 89.4% | 79.8% | 48.9% | |
Fair Value Upside | Unlock | 3.9% | 6.2% | Unlock |
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Atrium Therapeutics (RNA) Share Price Today?
The Atrium Therapeutics share price today is 13.20.
What is the current Atrium Therapeutics (RNA) share price and day range?
As of 23-08-2026, the Atrium Therapeutics share price is 13.20, with a previous close of 13.48. The share price has ranged from 12.96 to 13.59 today, while the 52-week range spans from 11.13 to 16.77.
What Is the Atrium Therapeutics Market Cap?
As of today, Atrium Therapeutics market cap is 225.79M.
What Is the Atrium Therapeutics (RNA) Share Price Target?
The average 12-month share price target for Atrium Therapeutics is 25.00, with a high estimate of 25 and a low estimate of 25. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +89.39% Upside potential.
What Is Atrium Therapeutics's Earnings Per Share (TTM)?
The Atrium Therapeutics EPS (TTM) is -3.86.
When Is the Next Atrium Therapeutics Earnings Date?
Atrium Therapeutics will release its next earnings report on 13-08-2026.
From a Technical Analysis Perspective, Is RNA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Atrium Therapeutics Trade On?
Atrium Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Atrium Therapeutics?
The stock symbol for Atrium Therapeutics is "RNA."
How Many Times Has Atrium Therapeutics Stock Split?
Atrium Therapeutics has split 0 times.
What Is the RNA Premarket Price?
RNA's last pre-market stock price is 12.10. The pre-market share volume is 10.00, and the stock has changed by -1.38, or -10.24%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.